[The effect of thrombocyte-derived growth factor on experimental inflammatory bowel disease].
The role of Platelet-Derived Growth Factor (PDGF) was investigated in treatment of experimental inflammatory bowel disease (IBD) in animal models. A new model of IBD induced by the sulfhydryl (SH) alkylator iodoacetamide revealed that the most appropriate concentration of iodoacetamide is 6% given intracolonically once. Daily treatment with PDGF dose-dependently accelerated the healing of colonic erosions, ulcers and inflammation.